CD8A and neoplasm: Adjuvant interleukin 7 (IL-7) treatment can elicit a significant increase in the number of antigen-specific effector and memory CD8+ T cells in several types of vaccine modules, including lentivirus-based or DNA-based vaccines.21 22 In particular, IL-7 can boost vaccine-induced antitumor immunity and enhance mouse survival in a tumor-bearing mouse model by enhancing the survival of activated T cells and cytolytic activity in vivo.23